Value of Information

Expected value of sample information (EVSI) 1 measures the average net-benefit gain from conducting new research and can be used to inform decisions on which new studies to fund and how best to design those studies. This helps avoid wasting resources researching treatments that were never likely to be cost-effective or conversely by adopting treatments that, if more evidence were collected, may be shown not to be cost-effective. However, the calculations in the general case rely on nested simulations, which can be very computationally demanding and even infeasible to compute in some cases. Since EVSI needs to be repeatedly computed over the potential study design space, this represents a clear barrier to the uptake of EVSI methods in practice. In some special situations, algebraic solutions are available that avoid the inner simulation step. 2–4 More generally, meta-modeling, which attempts to build a model to approximate the relationship between the model inputs (on which a new study can provide information) and model outputs (net benefit), is a promising approach that can lead to substantial computational savings. 5,6 In this issue, 2 novel meta-modeling methods are proposed for the calculation of EVSI, 7,8 both of which require only

[1]  Alex J. Sutton,et al.  Evidence Synthesis for Decision Making 2 , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[2]  A E Ades,et al.  Expected Value of Sample Information Calculations in Medical Decision Modeling , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.

[3]  Deborah M Caldwell,et al.  Expected Value of Sample Information for Multi-Arm Cluster Randomized Trials with Binary Outcomes , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.

[4]  Howard Raiffa,et al.  Applied Statistical Decision Theory. , 1961 .

[5]  M. Sculpher,et al.  Using Value of Information Analysis to Prioritise Health Research , 2012, PharmacoEconomics.

[6]  P Tappenden,et al.  Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis. , 2004, Health technology assessment.

[7]  Nicky J Welton,et al.  Evidence Synthesis for Decision Making in Healthcare , 2012 .

[8]  J. Madan,et al.  Strategies for Efficient Computation of the Expected Value of Partial Perfect Information , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.

[9]  Simon G Thompson,et al.  Structural and parameter uncertainty in Bayesian cost-effectiveness models , 2010, Journal of the Royal Statistical Society. Series C, Applied statistics.

[10]  Gianluca Baio,et al.  Bayesian Methods in Health Economics , 2012 .

[11]  A E Ades,et al.  An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. , 2012, Health technology assessment.

[12]  Simon G Thompson,et al.  Accounting for uncertainty in health economic decision models by using model averaging , 2009, Journal of the Royal Statistical Society. Series A,.

[13]  Hawre Jalal,et al.  Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression Metamodeling , 2015, Medical decision making : an international journal of the Society for Medical Decision Making.

[14]  Karl Claxton,et al.  Characterizing structural uncertainty in decision analytic models: a review and application of methods. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  Malcolm J Price,et al.  Model averaging in the presence of structural uncertainty about treatment effects: influence on treatment decision and expected value of information. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  Karl Claxton,et al.  Dimensions of Design Space: A Decision-Theoretic Approach to Optimal Research Design , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.

[17]  K Claxton,et al.  Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development. , 2012, Health technology assessment.

[18]  Nicky J Welton,et al.  Preventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses , 2007, BMJ : British Medical Journal.

[19]  Nicky J Welton,et al.  Evidence Synthesis for Decision Making in Healthcare: Welton/Evidence Synthesis for Decision Making in Healthcare , 2012 .

[20]  M D Stevenson,et al.  Gaussian Process Modeling in Conjunction with Individual Patient Simulation Modeling: A Case Study Describing the Calculation of Cost-Effectiveness Ratios for the Treatment of Established Osteoporosis , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.

[21]  Jeremy E. Oakley,et al.  Estimating the Expected Value of Sample Information Using the Probabilistic Sensitivity Analysis Sample , 2015, Medical decision making : an international journal of the Society for Medical Decision Making.

[22]  M. Sculpher,et al.  Bayesian methods for evidence synthesis in cost-effectiveness analysis , 2012, PharmacoEconomics.

[23]  H. Raiffa,et al.  Applied Statistical Decision Theory. , 1961 .